StockUS listing USALXONASDAQHealthcareEarnings Deterioration

Alx Oncology Holdings (ALXO) Stock Analysis | Healthcare

USD --+0.00%
Reward34Low
Risk42Moderate
75%Data
Revenue down 100% YoY
USD —+0.00 (+0.00%) Previous close · NASDAQ
Market cap 137.03M
Reward Ratingⓘ34 Low reward assessment · 75% data coverage
Bottom 5% of stocksView factors
Risk Ratingⓘ42 Moderate risk assessment
Risk factors availableUnlock details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on ALXO to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Alx Oncology Holdings ?

, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States.

AI Brief Pro

The brief on Alx Oncology Holdings 

The story behind the price, the case for and against, and what could go wrong. Open a part to read it.

What is Alx Oncology Holdings ?

, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 137.03M.

Financial Highlights

Investment Breakdown

Growth
Revenue growth is subdued, limiting near-term earnings expansion.
Profitability
Thin or inconsistent margins weigh on earnings quality.
Risk
Risk profile appears balanced versus broad market conditions.
Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Low (34)

Similar stocks to compare

A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.

Company Information
SectorHealthcare
IndustryBiotechnology
Market Cap137.03M
Beta0.557
Insider Activity
12M windowMixed
Shares soldShares bought
0-3months
0
0
3-6months
34,207 shares
$8k
0
6-9months
213,214 shares
$29k
0
9-12months
24,490 shares
$6k
13,184,713 shares
$5.0M